financial losses resulting from physical injury caused through 
the fault of the hospital, its employees or its agents. If 
physical injury occurs in the absence of such fault, the hospital 
does not provide reimbursement for treatment expenses or other 
compensation for physical injury suffered as a result of your 
participation in this study. 
If you believe that physical injury has been suffered as a 
result of participation in this study, you understand that you 
should contact Dr. Carl Lenarsky or Dr. Donald Kohn at (213) 669- 
2546. Treatment for such injury will be available under the same 
financial arrangements as treatment is usually provided. 
CONFIDENTIALITY 
Case histories, the results of treatment, laboratory and 
pathologic data, photographs, and x-rays may be published for 
scientific purposes, but your identity will not be disclosed and 
confidentiality will be maintained. The Food and Drug 
Administration (FDA) , the Department of Health and Human Services 
(DHHS) , and Genetic Therapy Inc., Amgen, Sandoz, CellPro, and/or 
their designate (s) may inspect the records relating to your 
participation in the study. If the study plan or use of the 
information is to be changed, you will be so informed. 
VOLUNTARY PARTICIPATION 
This study program has been reviewed, and its consent form 
has been approved by four boards: 1) the Childrens Hospital Los 
Angeles Committee on Clinical Investigations (IRB — Institutional 
Recombinant DNA Research, Volume 17 
[845J 
